IRISS registry study offers real-world outcomes

Investigators found that a fluocinolone acetonide implant maintained good real-world vision levels in patients with diabetic macular oedema who had good baseline vision.

DMO study shows robust efficacy of intravitreal dexamethasone implant

In a real-world study of patients with treatment-naïve and previously treated diabetic macular oedema, injection of intravitreal dexamethasone 0.7-mg implant provided effective disease control with initial and repeat injections, regardless of reinjection interval.

The quest for topical treatments for the posterior segment

Topical eye drop treatments for the posterior segment would offer easier, less invasive options than those currently available. This would reduce the burden on both patients and their caregivers, increasing adherence and improving outcomes.

Rapid Readout: Angiopoietin-2 (Ang2) Inhibition in the Treatment of Diabetic Macular Edema and Exudative AMD.

March 22, 2021

Anat Loewenstein, MD, MHA, discusses data from the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium on angiopoietin-2/VEGF-A dual inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.

Study targets strategies for CI-DMO

March 22, 2021

In the DRCR Retina Network Protocol V, which studied management strategies for eyes with centre-involving DMO and good visual acuity, the majority of eyes randomly assigned to initial observation completed the 2-year study without needing anti-VEGF therapy for vision loss and nearly one-third had spontaneous resolution of DMO.

Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives

March 03, 2021

Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.